进展期胃低分化腺癌术后综合中医治疗的临床疗效观察

Clinical observation on composite treatment of advanced gastric poorly differentiated adenocarcinoma after operation

目的 评价对进展期胃低分化腺癌术后中西医结合综合治疗的疗效。方法 采用口服自拟加减胃愈方联合OLF化疗方案治疗进展期低分化Ⅱ-Ⅲ级胃腺癌术后患者25例,并与单纯实施OLF方案化疗的25例随机对照,进行为期3年的生存期、生活质量、复发转移等情况的观察。结果 联合组3年存活率68.0%（17例）,对照组40.0%（10例）;联合组无进展生存率（PFS）达56.0%,明显高于单纯化疗对照组的28.0%;器官转移个数16个,明显低于对照组的31个;联合组在化疗期间的各类毒副反应症状发生率明显低于对照组。结论 口服自拟加减胃愈方联合OLF化疗的综合治疗方案治疗术后进展期胃低分化腺癌可防止复发转移,提高生存率。

Objective To evaluate the efficacy of combination of TCM with Western medicine in treatment of patients with advanced gastric poorly differentiated adenocarcinoma, Methods Fifty patients with stage Ⅱ -Ⅲ advanced poorly differentiated gastric cancer after operation were randomized into two groups of 25 patients each. Group I was treated with OLF regimen combined with self-constituted increase-decrease Weiyufang（TCM） ,group Ⅱ was treated with OLF regimen only as control. The survival, quality of life, recidivation and metastasis were observed for 3 years. Results The 3-year survival rates of the group I and group Ⅱ were 68.0% （ 17 cases） and 48.0% （ 12 cases） respectively （ P 〉 0.05 ） , and progression-free survival rates （PFS） were 56.0% and 28.0% （ P 〈 0. 05 ）. During treatment the numbers of organ metastasis were 16 and 31 respectively. The toxicity in group Ⅰ was obviously lower that in group Ⅱ. Conclusion Selfconstituted increase-decrease Weiyufang plus OLF regimen is more effective for advanced poorly differentiated gastric cancer after operation than pure chemotherapy in preventing recidivation and metastasis, as well as in elevating survival rates.